14 полученные результаты
TECHNICAL FIELD
The in relates to methods to treat patients with melanoma, specifically those who have become resistant to B-Raf inhibitors. The treatments employ multikinase inhibitors, especially those that inhibit receptors for VEGF, PDGF, IGF and FGF.
BACKGROUND ART
It has been reported by
The present invention relates to novel compounds useful as therapeutic agents and assay reagents. More specifically, the present invention relates to a drug targeting and especially to a novel method of delivery of therapeutically active agents to tumour cells, in particular melanoma
FIELD
This disclosure concerns the identification of novel mutations in members of the protein tyrosine (PTK) family, including ERBB4, and methods of use.
BACKGROUND
The protein tyrosine kinases (PTKs) are a family of proteins that catalyze phosphorylation of tyrosine residues in target proteins;
BACKGROUND OF THE INVENTION
Intercellular protein tyrosine phosphorylation is regulated by extracellular stimuli, such as cytokines, to control cell growth, differentiation and functional activities. This signaling mechanism depends on the interplay of protein tyrosine kinases, which initiate
BACKGROUND OF THE INVENTION
Intercellular protein tyrosine phosphorylation is regulated by extracellular stimuli, such as cytokines, to control cell growth, differentiation and functional activities. This signaling mechanism depends on the interplay of protein tyrosine kinases, which initiate
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF)
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF)
RELATED APPLICATION
This application is related to U.S. provisional patent application No. 61/015,019 filed 19 Dec. 2007, the contents of which are incorporated herein by reference in their entirety.
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds for
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF)
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain aryl-quinolyl compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF)
RELATED APPLICATIONS
This application is a national stage filing under 35 U.S.C. 371 of International Application No. PCT/GB2007/001534 filed 26 Apr. 2007, which is related to: United Kingdom patent application number 0608268.9 filed 26 Apr. 2006 and U.S. patent application No. 60/745,633 filed 26
FIELD OF THE INVENTION
The present invention in general relates to a method of inhibiting cell motility and angiogenesis and treating various diseases in a mammal, and particularly to a method of inhibiting cell motility and angiogenesis induced by the hepatocyte growth factor (HGF). The present
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds for treating proliferative conditions, cancer, etc., and more specifically to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereofwhich, inter alia, inhibit RAF